source
- Beam Therapeutics' base-edited sickle cell therapy shows success in Phase 1/2 trialBeam Therapeutics announced on Tuesday that its base-edited gene therapy for sickle cell disease met its primary endpoints in a Phase 1/2 study. The trial demonstrated that a single administration…
- Coherus trims workforce by 30% as Gyre Therapeutics also cuts staff after acquisitionCoherus Oncology announced a 30% reduction in its workforce as part of a reorganization that narrows its pipeline. The cuts follow a decision to deprioritize a combination therapy across multiple…